NL-OMON38562撤回不适用
SOM230 Graves Orbitopathy pilot trial - SOMGO
适应症
试验速览
- 阶段
- 不适用
- 状态
- 撤回
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •-moderate * severe GO
- •-corticosteroids contraindicated due to diabetes mellitus (see below), severe
- •osteoporosis, heart failure, psychosis, infectious diseases or other clinical relevant
- •comorbidities
- •-corticosteroids refused by patients
- •-age > 18
排除标准
- •-inability/refusal to give informed consent
- •-pregnancy
- •-GO (dysthyroid optical neuropathy) necessitating high dose steroids or acute
- •decompression
- •-abnormal thyroid function (defined as TSH >4.0 mU/l or FT4 <10 or >21 pmol/l)
- •-pregnancy
- •-drug abuse and smoking.
研究者
相似试验
招募中
不适用
Pilot study of SOM230 for Treatment of Graves’ OphthalmopathyDiseases of the eye and adnexaKCT0001645Yonsei University Health System, Severance Hospital20
尚未招募
不适用
SOM230 Graves Orbitopathy pilot trial.Graves OrbitopathyNL-OMON26944Academic Medical Center Amsterdam12
进行中（未招募）
1 期
Phase I trial: Ocular Technology Group International CV23-08The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.ISRCTN66819383CooperVision International Ltd40
进行中（未招募）
1 期
Phase I trial: Ocular Technology Group InternationalThe Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.ISRCTN90702227CooperVision International Limited20
尚未招募
2 期
Sirolimus for Graves' Orbitopathy (GO)Graves OphthalmopathyNCT04598815University of Pisa54